Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2509-2512

  Alastruey Izquierdo, Ana ^a   Gómez López, Alicia ^a   Arendrup, Maiken C ^b   Lass Florl, Cornelia ^c   Hope, William W ^d   Perlin, David S ^e   Rodriguez Tudela, Juan L ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b STATENS SERUM INSTITUT   (Denmark)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; DIMETHYL SULFOXIDE; MICAFUNGIN; WATER;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GENOTYPE; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SOLVENT EFFECT;

ANTIFUNGAL AGENTS; CANDIDA; DIMETHYL SULFOXIDE; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; SOLVENTS; WATER;

EID: 84862729632     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00791-12     Document Type: Article

References (20)

1. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, the EUCAST-AFST. 30 April 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EDef 7.2 (EUCAST-AFST)*. Clin. Microbiol. Infect. [Epub ahead of print.] doi: 10.1111/j.1469-0691.2012.03880.x.
2. Arendrup MC, et al. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
3. Arendrup MC, et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob. Agents Chemother. 54:426-439.
4. Arendrup MC, et al. 2011. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587.
5. Baixench MT, et al. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
6. Blanchard E, et al. 2011. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob. Agents Chemother. 55:5358-5361.
7. Castanheira M, et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
8. Desnos-Ollivier M, et al. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
9. Durán-Valle MT, et al. 2012. Recurrent episodes of candidemia due to Candida glabrata with a mutation in the hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob. Agents Chemother. [Epub ahead of print.] doi:10.1128/AAC.06100-11.
10. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
11. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
12. Garcia-Effron G, Park S, Perlin DS. 2011. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob. Agents Chemother. 55:2245-2255.
13. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
14. Perlin DS. 2011. Current perspectives on echinocandin class drugs. Future Microbiol. 6:441-457.
15. Pfaller MA, et al. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50:1199-1203.
16. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
17. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
18. Rodriguez-Tudela JL, et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
19. St-Germain G, et al. 2008. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19:55-62.
20. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.